To receive and adopt the Companys accounts for the financial year ended 31 December 2024 and the associated reports of the Directors and auditors (the 2024 Annual Report and Accounts).
To approve the Directors remuneration report (excluding the Directors remuneration policy set out on pages 39 to 52 of Directors remuneration report), which is set out on pages 36 to 65 of the 2024 Annual Report and Accounts.
To approve the Directors remuneration policy set out on pages 39 to 52 within the Directors remuneration report contained in the 2024 Annual Report and Accounts, which will take effect immediately after the end of the AGM.
To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of the 2025 AGM until the conclusion of the 2026 AGM and to authorise the Directors to determine the auditors remuneration.
To re-elect Dr. R Iannone as a Director.
To re-elect Dr. R Rao as a Director.
To approve the Autolus Therapeutics plc Employee Share Purchase Plan with Sharesave Sub-Plan adopted by the Board on 20 May 2025 (the Purchase Plan), with 3,000,000 (three million) Shares (as defined therein) available for issuance under the Purchase Plan, and with the directors authorised to do all acts and things as are or may be necessary or expedient to carry the same into effect, notwithstanding that the directors may be interested in the same.